NCT01253655View on ClinicalTrials.gov

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Healthy
Interventions
DRUG

PF-05212365

Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.

Trial Locations (3)

06511

Pfizer Investigational Site, New Haven

06519

Pfizer Investigational Site, New Haven

06520

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Yale University

OTHER

lead

Pfizer

INDUSTRY